• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Propanc Biopharma, Inc. - Common Stock (NQ:PPCB)

    1.185 -0.165 (-12.22%)
    Streaming Delayed Price Updated: 1:27 PM EDT, Sep 1, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Propanc Biopharma, Inc. - Common Stock

    < Previous 1 2 Next >
    News headline image
    Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit
    Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
    Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers
    Contrasting Science with Revolution Medicines and Erasca 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models
    Accelerates Phase 1b First-in-Human Trial Timeline 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program
    Purchasing $500,000 within First 30 days Since Program Commencement 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal
    A Promising Strategy for Improving Production for Applications in Biotechnology Research 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd
    Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Initiates $5.0 Million Share Repurchase Program
    The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
    Pre-production, Engineering Run and GMP Manufacture of PRP in 2026 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
    Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain
    Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
    Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
    Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
    Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From Rosen Law Firm
    Via Business Wire
    News headline image
    Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB
    From The Rosen Law Firm, P.A.
    Via Business Wire
    News headline image
    Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
    Fifth Agreement between Propanc & the Universities over a 17yr Period 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
    Root-Cause Attack. Chemo Sensitization. Safer Profile. 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
    A German CDO Supporting Biotech Companies Bringing Biologics from Early Development to Clinic 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
    PRP May Outshine Traditional Therapies in a Booming $4.4 Billion Market 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations
    Key Milestone Builds Toward Doubling Patent Portfolio to Over 200 Worldwide – Positioning Propanc as a Long-Term Leader in Metastatic Cancer Prevention 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
    A World-First, Fully Synthetic Recombinant Version of PRP 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer
    The Science, Clinical Promise, & Market Outlook 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Provides Shareholder Update
    CEO Highlights Significant Progress Achieved & Outlines Ambitious Plans for 2026 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal
    Results Underscore PRP Candidacy as a Disruptor of the Tumor Microenvironment 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
    Joint Research Team Focusing on Impact of PRP Reversal of EMT Pathways as Central Role 
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    News headline image
    Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis
    From Propanc Biopharma, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.